Search Results
120 items found for "Ermium Therapeutics"
- Ep 113 with Dr. Prasenjit Saha
receptors would be a significant breakthrough in cardiovascular biology as they could be targeted for therapeutic
- Gallein, G protein βγ subunits inhibitor, suppresses the TGF-α-induced migration of hepatocellular carcinoma cells via inhibition of the c-Jun N-terminal kinase
Small molecules targeting the subunits of Gα and Gβγ have been developed as cancer therapeutics.
- Leukotriene B4 receptor 2 governs macrophage migration during tissue inflammation
demonstrate that BLT2 mediates macrophage migration during inflammation, which implicates it as a potential therapeutic
- GPR176 promotes fibroblast-to-myofibroblast transition in organ fibrosis progression
Developing a GPR176 inverse agonist or allosteric modulator is a promising therapeutic approach for fibrosis
- Minireview: functional roles of tissue kallikrein, kinins, and kallikrein-related peptidases in lung cancer
Furthermore, their modulation could be considered as a promising approach in lung cancer therapeutics
- Agonists of galanin subtype 2 receptor may prevent pancreatic cancer and agonists of angiotensin II type 2 receptor may prevent colorectal cancer
agonist enhances expression of GAL2 receptor, not only in PDAC-PDX but also in healthy tissue indicating therapeutic
- Simultaneous activation of CXC chemokine receptor 4 and histamine receptor H1 enhances calcium signaling and cancer cell migration
interplay between CXCR4 and HRH1, and suggest the possibility of the CXCR4-HRH1 heteromer as a potential therapeutic
- S1P Signaling Genes as Prominent Drivers of BCR-ABL1-Independent Imatinib Resistance and Six Herbal Compounds as Potential Drugs for Chronic Myeloid Leukemia
Moreover, the S1P signaling genes are promising therapeutic targets and plausible new innovation avenues
- Pharmacological inhibition of neuropeptide Y receptors Y1 and Y5 reduces hypoxic breast cancer migration, proliferation, and signaling
Therefore, these antagonists may aid in the development of novel cancer therapeutics and patient-based
- Ep 153 with Dr Jacek Mokrosiński
Yamina will schedule a future talk with Jacek about GPCRs as therapeutic modalities. The discussion revealed their interest in GPCRs as therapeutic modalities and possible future collaborations
- Ep 146 with Dr Michael Feigin
Michael Feigin is an Associate Professor in the Department of Pharmacology and Therapeutics, and Director of Graduate Studies of Experimental Therapeutics at Roswell Park Comprehensive Cancer Center in Buffalo disrupting histone processing on rapidly proliferating cells, such as cancer cells, and suggested a therapeutic
- Advanced data analysis for GPCR pharmacology | Dr. GPCR Ecosystem
drug action and is known for applying binding and signaling kinetics to the development of effective therapeutics
- Ep 36 with Dr. Michel Bouvier
of Canada (2014), the Julie Axelrod award from the American Society of Pharmacology and Exerimental Therapeutics
- A disturbed metabolite-GPCR axis is associated with microbial dysbiosis in IBD patients: Potential role of GPR109A in macrophages
better understanding of metabolite-sensing GPCRs, such as GPR109A, could establish their potential as therapeutic
- G protein-coupled receptors: A target for microbial metabolites and a mechanistic link to microbiome-immune-brain interactions
an improved understanding of gut microbiota-immune-brain molecular interactions and their potential therapeutic
- Wnt pathway inhibition with the porcupine inhibitor LGK974 decreases trabecular bone but not fibrosis in a murine model with fibrotic bone
targeting the Gs-GPCR or components of the downstream signaling pathway could serve as a promising therapeutic
- GPR15 expressed in T lymphocytes from RA patients is involved in leukocyte chemotaxis to the synovium
Our results suggest that GPR15/GPR15L have a pathogenic role in RA and their antagonizing could be a therapeutic
- Prediction of survival and immunotherapy response by the combined classifier of G protein-coupled receptors and tumor microenvironment in melanoma
mediator in the advancement of OSCC, offering a potential avenue for the development of innovative therapeutic
- TIPE proteins control directed migration of human T cells by directing GPCR and lipid second messenger signaling
These findings have implications for therapeutically targeting TIPE proteins in human inflammatory and
- Systems Pharmacodynamic Model of Combination Gemcitabine and Trabectedin in Pancreatic Cancer Cells. Part II: Cell Cycle, DNA Damage Response, and Apoptosis Pathways
pancreatic adenocarcinoma (PDAC) continues to present a formidable clinical challenge, demanding innovative therapeutic
- CaaX-motif-adjacent residues influence G protein gamma (Gγ) prenylation under suboptimal conditions
Pharmacological inhibition of the lipid synthesis pathway by statins is a therapeutic approach to control
- Flash News / DrGPCR
subtype-selective precision by combining allosteric modulation with light control, paving the way for new therapeutic essential additional elements to GPCR discovery programs that extend the discovery process and increase therapeutic
- Activation of PI3K/Akt pathway by G protein-coupled receptor 37 promotes resistance to cisplatin-induced apoptosis in non-small cell lung cancer
Therefore, our findings demonstrated that GPR37 may represent a viable therapeutic target for NSCLC."
- The orphan G protein-coupled receptor 141 expressed in myeloid cells functions as an inflammation suppressor
controlling the functions of monocytes and dendritic cells and that targeting GPR141 may be a possible therapeutic
- RGS20 promotes non-small cell lung carcinoma proliferation via autophagy activation and inhibition of the PKA-Hippo signaling pathway
inhibition of the PKA-Hippo signaling pathway Published date March 2, 2024 Abstract " Background: Novel therapeutic
- Interplay between G protein-coupled receptors and nanotechnology
understanding of the designated value of GPCRs for molecular engineering of biomaterials with GPCRs in therapeutical
- Investigating isoform switching in RHBDF2 and its role in neoplastic growth in breast cancer
In the past, studies predicting therapeutic drug targets for cancer therapy focused on the assumption
- Session II | Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem
understanding the molecular basis for human tumor development and how to use this knowledge to devise new therapeutics Van Meir has developed novel therapeutic approaches for cancer using oncolytic adenoviruses and anti-angiogenic